Roche Holding earnings calendar in focus, shares watched on SIX

Roche Holding AG faces a dense earnings calendar in the coming weeks, with investors on SIX Swiss Exchange watching pharmaceutical peers and consensus expectations closely.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 20:23.

Roche Holding AG (CH0012032048) is heading toward its next financial updates with investors on SIX Swiss Exchange closely tracking expectations for the Swiss pharma major. The timetable for half-year and nine-month figures, as listed on the company's investor relations calendar, structures the coming reporting season for the stock.

Upcoming dates on the Roche calendar

Roche's official investor relations site lists its regular interim reporting, including half-year and nine-month sales and results, which typically act as catalysts for the shares. The group follows a pattern similar to peers Novartis and Sanofi, with half-year figures usually presented in the summer and an investor event around full-year reporting at the start of the year. The Roche investor relations calendar sets out the detailed timetable for results and events.

Analyst services such as MarketScreener and financial portals like Investing.com compile consensus expectations for Roche's upcoming results, summarizing estimates for core earnings per share, sales growth and dividend development. These consensus snapshots, often aggregated from banks such as UBS, Credit Suisse and Deutsche Bank, frame how the market may react when Roche publishes its next set of numbers. MarketScreener's Roche consensus page tracks these aggregated estimates.

How analysts view Roche shares

Major investment banks regularly update their views on Roche, with a mix of Buy, Hold and Sell ratings reflecting differing opinions on the company's pipeline and patent exposure. Recent analyst reports, as summarized by financial data providers, often highlight Roche's oncology franchise and diagnostics segment as key profit drivers, while also noting competitive pressure from biosimilars and other large pharmas. Investing.com provides an overview of Roche's analyst ratings, target prices and valuation multiples.

For international investors comparing large-cap healthcare names in indices such as the SMI and Stoxx Europe 600, Roche sits alongside peers like Novartis, AstraZeneca and Pfizer in many global portfolios. Analyst commentary frequently compares valuation metrics such as price-to-earnings and dividend yield across this peer group, with Roche often positioned as a defensive healthcare holding thanks to its stable cash flows and diversified revenue base. Reuters key metrics for Roche summarize these valuation and performance indicators.

What Roche sells and develops

Roche generates most of its revenue from prescription medicines in oncology, immunology, neurology and ophthalmology, complemented by a large diagnostics business spanning laboratory systems and point-of-care tests. A representative product from its innovative portfolio is Tecentriq, an immunotherapy used in various cancer indications.

Where the stock trades today

Roche Holding AG shares most recently traded on SIX Swiss Exchange in Zurich; the latest available price data point serves as the reference for investors following the Swiss blue-chip healthcare name.

Roche Holding AG at a glance

• Company: Roche Holding AG
• ISIN: CH0012032048
• WKN: 851311
• Ticker: ROG
• Trading venue: SIX Swiss Exchange
• Price (as of 2026-06-29, 18:10): 235.00 CHF
• Market cap: 202.0 billion CHF (as of 2026-06-29)
• Sector / industry: Health Care - Pharmaceuticals & Biotechnology
• Index membership: SMI, Stoxx Europe 600
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.